<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000541</url>
  </required_header>
  <id_info>
    <org_study_id>3319</org_study_id>
    <nct_id>NCT05000541</nct_id>
  </id_info>
  <brief_title>Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical</brief_title>
  <official_title>Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical , in Subjects With Hypercholesterolemia at Low-moderate Cardiovascular Risk Not Requiring a Drug Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Österreich GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Germany GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Healthcare Sp. z o.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present multinational, multicentre, prospective, scientific study is to&#xD;
      confirm that prescription of a low-dose red yeast-based nutraceutical.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present multinational, multicentre, prospective, scientific study is to&#xD;
      confirm that prescription of a low-dose red yeast-based nutraceutical significantly increases&#xD;
      the LDL-C lowering effect of guideline-driven lifestyle interventions in subjects with&#xD;
      hypercholesterolemia at low-moderate cardiovascular risk not requiring a drug therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in LDL-C</measure>
    <time_frame>3 months</time_frame>
    <description>Mean change from baseline in LDL-C at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects' adherence to the prescribed lifestyle interventions measured on VAS</measure>
    <time_frame>at 3 months and 6 months</time_frame>
    <description>Subjects' adherence (at 3 months and 6 months) to the prescribed lifestyle interventions measured on VAS (Visual Analogue Scale)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Armolipid-L/Armolipid Plus-L</arm_group_label>
    <description>Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects to be enrolled are subjects already in primary prevention for CVD for raised LDL-C&#xD;
        and who, according to the intervention strategies recommended in Table 5 of the ESC/EAS&#xD;
        guidelines (lifestyle interventions, consider drug if uncontrolled) had been prescribed, in&#xD;
        the previous 3 months, only dietary advices and physical exercise.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 25 and 75 years;&#xD;
&#xD;
          -  In primary prevention for low-moderate CV risk, with diet and physical exercise to&#xD;
             control raised LDL-C level, for at least 3 months;&#xD;
&#xD;
          -  LDL-C &gt; 100 mg/dL (2.6 mmol/L), &lt; 190 mg/dL (4.9 mmol/L)&#xD;
&#xD;
          -  CV risk SCORE &lt;5% (based on SCORE chart according to figure I for Poland respective&#xD;
             figure 2 for Austria and Germany in the ESC/EAS guideline 2019);&#xD;
&#xD;
          -  Triglyceride &lt;400 mg/dL;&#xD;
&#xD;
          -  Advised to use nutraceutical as part of the lifestyle intervention as per guideline&#xD;
             and within the product label (i.e. posology as in product label);&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects being treated or who have been treated for up to 3 months before the start of&#xD;
             the study with lipid-lowering drugs or nutraceuticals including functional foods for&#xD;
             which lipid-lowering effects are known (e.g. fish oil, sterol-containing yoghurts&#xD;
             etc.);&#xD;
&#xD;
          -  Subjects involved in other clinical studies with pharmaceutical products&#xD;
&#xD;
          -  Known laboratory evidence of either liver, muscle, thyroid or kidney dysfunction;&#xD;
&#xD;
          -  Subjects with prior history of cardiovascular events or with high cardiovascular risk&#xD;
             equivalents;&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;190 mmHg or diastolic blood&#xD;
             pressure &gt;100 mmHg);&#xD;
&#xD;
          -  Pregnancy and breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uwe Buermann</last_name>
    <phone>+49 6127 888</phone>
    <phone_ext>2527</phone_ext>
    <email>uwe.buermann@viatris.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Emmeluth</last_name>
    <phone>+49 6127 888</phone>
    <phone_ext>1194</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ordination</name>
      <address>
        <city>Unterhautzenthal</city>
        <zip>2011</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Györög, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordination</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertraud Woda, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Bexbach</city>
        <zip>66450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Ganz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Deggingen</city>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jung, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Frankfurt</city>
        <zip>60598</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Görlitz</city>
        <zip>02827</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Oettler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AmBeNet GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Detlev Stahl, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

